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Perturbations of the Immune System by
Xenobiotics
by Michael 1. Luster,* Michael F. Ackermann,*
Dori R. Germolec,* and Gary J. Rosenthal*
Classically, immunotoxicology has been defined as the study ofadverse effects on the immune system as-
sociated with exposure to environmental chemicals, pharmacologic agents, and biologicals. Although a mul-
titude ofimmune system defects may occur, these can be generally categorized as immunomodulation (im-
mune suppression orpotentiation), hypersensitivity (i.e., allergy), and autoimmunity. We present here a brief
synopsis ofthe ontogeny ofimmunotoxicology as a discipline including methodology currently used in our
laboratory, as well as in others, for investigating the immunomodulatory potential ofchemicals at the cellu-
larand biochemical level. Additionally, we summarize some studies related to the immunosuppressive effects
ofone particular compound, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). Last we discuss potential future
directions and challenges in the field ofimmunotoxicology.
Background
Immunotoxicology can be defined as the study of the
adverse effects ofenvironmental chemicals, certain ther-
apeutics, and biologicals on the immune system. The ad-
verse effects that may occur include immunomodulation
(i.e., suppression orpotentiation), hypersensitivity (i.e., al-
lergy), and, in rare instances, autoimmunity. Although
chemical-induced autoimmune diseases are not well
documented, the extent ofchemical-induced hypersensi-
tivity has been known for a long time (1,2). Some ofthe
industrial materials with known or presumed allergic
etiology are shown inTable 1. More recently, alarge body
ofinformation has also developed demonstrating that ex-
posure to certain chemicals or drugs can produce im-
munosuppression in experimental animals(Thble 2)(3-5).
In contrast to immunosuppressive drugs, however, only
alimitednumber ofreports indicate immune dysfunction
following a human exposure to chemical xenobiotics.
The sensitivity of the immune system to these chemi-
cals isprobably due as much to thegeneralproperties of
the xenobiotic (eg. reactivity with macromolecules) as to
the complex nature ofthe immune system, which encom-
passes antigen recognition andprocessing; cellular inter-
actions involving cooperation, regulation, and amplifica-
tion; cell activation, proliferation, and differentiation; and
*Division ofTexicology Research and Testing, National Institute ofEn-
vironmental Health Sciences, Research Triangle Park, NC 27709.
Address reprint requests to M. I. Luster, Division ofTbxicology Re-
search and Testing, National Institute ofEnvironmental Health Sciences,
P. 0. Box 12233, Research Tliangle Park, NC 27709.
mediator production. The immunosuppressive effects as-
sociated with exposure to xenobiotics are often accompa-
nied by increased susceptibility to challenge with infec-
tious agents or tumor cells. Although onlylimited studies
in humans have been conducted, effects similar to those
observed in rodents have been reported in several in-
stances following therapeutic, inadvertent, or occupa-
tional exposure to xenobiotics exemplifying characteris-
T'able 1. Industrial materials known or presumed to cause
allergic problems.a
Material
Platinum salts
Cotton dusts
Castor bean, green coffee bean
papain, pancreatic extracts, organic
dusts, and molds
Formaldehyde
Grain and flour
Hog trypsin, ethylenediamine
phthalic anhydride, beryllium
trimellitic anhydride, and
diisocyanates (TDI, HDI, and MDI)
Phenylglycine acid chloride,
sulfone chloramides, ampicillin,
spiramycin, piperazine, amprolium
hydrochloride, and antibiotic dust
Wood dusts
Vegetable gums (acacia, karaya)
and natural resins
Organophosphate insecticides
Pyrolysis products ofpolyvinyl
chloride and label adhesives
aModified from Luster and Dean (2).
Industry
Metal-refining
Iextile
Oil and food
Garment, laboratory
Farmers, bakers, and
mill operators
Chemical, plastic,
rubber, and resin
Pharmaceutical
Wood mills, carpenters
Printers
Farmers
Meat wrappersLUSTER ET AL.
Table 2. Examples of immunological abnormalities associated with chemical exposure in rodents and humans.
Laboratory immune Human immune
Chemical class Example abnormality abnormalitya
Polyhalogenated aromatic TCCD + +
hydrocarbons PCB + +
PBB + +
HCB + NK
Heavy metals Lead +
Cadmium +
Methyl mercury +
Aromatic hydrocarbons (solvents) Benzene + +
Toluene + +
Polycyclic aromatic hydrocarbons DMBA + NK
BaP + NK
MCA + NK
Pesticides O,O,S-TMP + NK
Carbofuran + NK
Chlordane + NK
Organotins DOTC + NK
DBTC + NK
Aromatic amines Benzidine + +
Oxidant gases (air pollutants) NO2 + NK
03 + +
SO2 + NK
Others Asbestos + +
DMN + NK
aNK not known; ±, positive and negative findings have been reported.
tics ofsecondary immunodeficiency disease. Amongthese
effects include altered immune responses in Michigan
residents and farmers exposed to polybrominated
biphenyls (PBBs) through the consumption of contami-
nated livestock and dairy products (6); Chinese and Jap-
anese exposed to polychlorinated biphenyls (PCBs) and
dibenzofuransthrough contaminated riceoilusedincook-
ing(7); Spanish residents exhibiting "toxic oil syndrome"
following ingestion of isothiocyanate-derived imidazo-
lidinethione adulterated rapeseed oil(8); factory workers
withaplastic anemiaandleukemiaoccupationallyexposed
to benzene (9); andAIDSpatients who develop myelotox-
icity following azidothymidine (AZT) therapy (10).
Increased susceptibility to infectious disease and ne-
oplasia has been a recurring consequence ofchronic im-
munosuppression or aberrant lymphoid cell differentia-
tion in several of these cohorts. For example, the
frequencyofneoplasia amongMichiganPBB-cohort mem-
bers exhibiting immune dysfunction is approximately
15-fold greater than that observed in the controlWiscon-
sin farmer cohort (J. G. Bekesi, personal communication).
These concerns are also supportedby the side effects as-
sociated with the therapeutic use ofchemicalimmunosup-
pressants that are used to treat certain autoimmune,
collagen-vascular, and chronic inflammatory diseases, as
well as to prevent rejection oftransplanted organs. For
example, therapeutic immunosuppression frequently
causes complications from bacterial, viral, fungal, and
parasitic infections.
Another complication ofimmunosuppression in trans-
plant patients has been a high frequency of secondary
cancers (11). Partial orcomplete regression ofthe secon-
dary cancers often occurs ifthe therapy is terminated. In
a large sampling of renal transplant patients who sur-
vived 10years, approximately 50% developed cancer. The
types of tumors observed were heterogenous and in-
cluded skin and lip cancer (21-fold increase over the
general population), non-Hodgkin's lymphomas (28- to
49-fold increase), Kaposi's sarcoma (400- to 500-fold in-
crease), and carcinomas of the cervix (14-fold increase).
These examples suggest that perturbations in the im-
mune systemmaybe associatedwith awide spectrum of
diverse pathologic conditions, some ofwhichmay onlybe-
come detectable after a long latency. However, whether
exposure to xenobiotics present in the environment in-
fluences immunocompetence ofthe generalpopulation un-
dernonnal circumstancesisnotknown andremains acen-
tral question.
Methodology
The immune systemis a complex network comprised of
several cell types (i.e., lymphocytes, macrophages,
granulocytes, and natural killer cells) whose variety of
functions include maintainghomeostasis and health. The
mode ofits activity resembles that ofthe endocrine sys-
tem in that circulating cellular and soluble components
can act at sites farremovedfromtheirpoint oforigin. The
system continuously undergoes proliferation and differen-
tiation. Its primary responsibility is the defense against
invasion by pathogenic microbial agents and spontane-
ously arising neoplasms. In doing so, the intensity and
specificity ofthe immune response mustbe highly regu-
lated and capable of discerning self from nonself.
Since the immune system is a complex organization of
cells with avariety offunctions, appropriate evaluation of
chemical-mediated effects necessitates the examination of
multiple immune functions. One ofthe focusesamongim-
munotoxicologists has been the development and im-
plementation of a tiered panel of assays to identify im-
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Table 3. Panel for detecting immune alterations following chemical or drug exposure in rodents.a
Parameter
Screen (Tier I)
Immunopathology
Humoral-mediated immunity
Cell-mediated immunity
Nonspecific immunity
Comprehensive (Tier II)
Immunopathology
Humoral-mediated immunity
Cell-mediated immunity
Nonspecific immunity
Host resistance challenge
Models (end points)b
Procedures
Hematology: complete blood count and differential
Weights: body, spleen, thymus, kidney, liver
Cellularity: spleen
Histology: spleen, thymus, lymph node
Enumerate IgM antibody plaque-forming cells to T-dependent
antigen (SRBC); LPS mitogen response
Lymphocyte blastogenesis to mitogens (Con A) and mixed
leukocyte response against allogeneic leukocytes
Natural killer (NK) cell activity
Quantitation of splenic B- and T-cell numbers
Enumeration of IgG antibody response to SRBCs
Cytotoxic T-lymphocyte (CTL) cytolysis; delayed hypersensitivity
response (DHR)
Macrophage function [quantitation of resident peritoneal cells and
phagocytic ability (basal and activated by MAF)]
Syngeneic tumor cells
PYB6 sarcoma (tumor incidence)
B16F10 melanoma (lung burden)
Bacterial models
Listeria monocytogenes (mortality)
Streptococcus species (mortality)
Viral models
Influenza (mortality)
Parasite models
Plasmodium yoelli (Parasitemia)
aThe testing panel was developed using B6C3F1 female mice.
bFor any particular chemical being tested, only two or three host resistance models are examined.
munosuppression or enhancement. The National
Toxicology Program (NTP) at the National Institute of
Environmental Health Sciences (NIEHS) uses aflexible
testing panel composed of two tiers (Table 3). This test-
ing configuration has undergone a4-year developmental
andinterlaboratory validation period (12) andis now rou-
tinely used to evaluate the potential oftherapeutic or en-
vironmental chemicals to modulate immune function in
mice. Immune testing configurations have also been
described in rats (13,14).
The assayslistedunder Tier I represent asimple screen
and include measurements for cell-mediated immunity
(CMI), humoral-mediated immunity (HMI), and natural
killer(NK) cell activity, as well as immunopathology, the
latter of which is part of the standard protocol in sub-
chronic studies conducted by the NTP. The likelihood of
detectingpotent immunotoxicants using Tier I ishigh, but
will decrease forweaker immunotoxicants, such as those
that affect only a specific cellpopulation or subpopulation.
Nonetheless, based upon the data from compounds that
have completed both Tier I and II testing, no compound
has been found to affect an assay in Tier II without dem-
onstrating some effect on Tier I.
The assays listed in Tier II, which allow more flexibil-
ity than Tier I, represent a more comprehensive evalua-
tion of the immune system, more likely to identify af-
fected cell types. Criteria usually fulfilled prior to
initiating tests in Tier II include lack ofovert toxicity at
doses where altered immune function(s) are observed in
Tier I and evidence that immunotoxicity occurs at rele-
vant dose levels. Withpharmaceuticals, this relates to the
anticipated therapeutic dose, while with environmental
chemicals, this would depend on the anticipated or
documented human exposure levels. Evidence ofa dose-
responserelationship wouldalsobe animportantprereq-
uisiteforproceedingto Tier II. The types ofassaysused
inTier II include quantitation ofsplenic B- andT-cells, in-
cluding subpopulations, secondary (IgG) antibody
responses, T-cell effectorfunction, andmacrophage activ-
ity, aswell as resistance to challenge with tumor cells or
infectious agents.
RegardingCMI, we have examinedboth delayedhyper-
sensitivity responses (DHRs) and cytotoxic T-lymphocyte
(CTL)activity, andaccumulating evidence indicates that
the latter provides more sensitivity and reproducibility
for assessing chemical-induced immunotoxicity. The use
ofmultiple assays in atestingconfiguration allows the es-
tablishment ofan immune profile similar to that used to
diagnose primary or acquired immunodeficiency diseases.
Because of the variability in some of the immune
responses, an alteration in a single parameter isnormally
insufficient to label a compound as immunotoxic. Details
describing these methodologies are published elsewhere
(12,15).
Hostresistance models were developed to evaluate the
relationship between the immune function tests and more
biologically relevant end points (16,17). This was partic-
ularlyimportant ifthe immunological data are tobe used
in risk assessment evaluation. The host resistance models
listedinTable 3 have been correlated with immune func-
tion assays using data from animals exposed to approxi-
mately 15 chemicals over a 4-year period (Table 4). In
general, changes in specific immune functions correlated
with certain host resistance assays. For example, in-
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creased suppression ofthe antibody plaque-forming cell
response and proliferative response to lipopolysaccharide
were accompanied by increased susceptibility following
challenge with influenza virus and mouse malaria (Plas-
modium), agents inwhichresistance ismediated, atleast
in part, by antibody. The correlation observed between
functional measurements and challenge models, albeit
preliminary, attempts to provide insight into the biologi-
cal significance ofthe various measures ofimmune func-
tion studied. This type ofanalysis should provide a bet-
ter understanding of the relevant immune effector
mechanism(s) involved in host resistance, as well as the
degree ofsuppression ofimmune function necessary to al-
ter host resistance (i.e., functional reserve). Additional
qualitative and quantitative information in this area
should also improve the accuracy with which the effects
of chemicals or drugs on the immune system can be
predicted.
Immunotoxic Xenobiotics
Of the list of immunotoxic compounds shown in Table
2, one ofthe most extensively studied classes ofenviron-
mental chemicals examined for immunotoxicity in ex-
perimental animals or humans is the halogenated aro-
matic hydrocarbons (HAHs), and, in particular,
polychlorinated biphenyls (PCBs), polybrominated
biphenyls (PBBs), dibenzo-p-dioxins, and dibenzofurans.
Despite the species variability associated with the toxic-
ity ofthese compounds, studies in laboratory animals ex-
posed during neonatal or adult life with HAHs and, in
particular, 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD),
have indicated that the immune system is one ofthe most
sensitive targets for toxicity (5,18-20). In mice, TCDD
causes thymic atrophy, myelotoxicity, inhibition of the
complement system, suppression oflymphocytefunctions,
and increased susceptibility to challenge with infectious
agents ortransplantable tumor cells. In contrast, NK cell
activity and macrophage functions appear spared. The
type ofeffect observedis dependent, to alarge extent, on
the age of the animal at the time of exposure.
Following perinatal or, in some cases, chronic exposure,
the primary immune effects are associated with thymic
atrophy and suppression ofcell-mediated immunity that
mimics neonatal thymectomy. Altered differentiation of
intrathymic precursor cells, as occurs following neonatal
thymectomy, has not been evaluated following perinatal
TCDD exposurea However, T-cellsfrom treated mice dem-
onstrate altered homing patterns (19), a feature charac-
teristic ofundifferentiated T-cells. Furthermore, in vitro
studies using athymocyte andthymic epithelial cell cocul-
ture system have shown that pretreatment of thymic
epithelial cell monolayers with TCDD inhibits their abil-
ity to stimulate T-cell differentiation (21). With the use of
murine bone-marrow chimeras, ithas been shown that in-
hibition ofCILs by subchronic TCDD exposure is due to
the Ah genotype ofthe host and not ofthe grafted stem
cell, further supporting involvement of a secondary tis-
sue (22). In contrast to subehronic orperinatal exposure,
acute exposure of adult rodents to HAHs has its major
effect on rapidly proliferating cell populations, including
hematopoietic stem cells and B-lymphocytes, the effect
manifested as suppressed antibody responses. Unlike
CMI, TCDD inhibits hematopoiesis and B-cell function by
directly inhibiting maturation of the B-lymphocytes or
bone marrow stem cell.
Myelotoxicity, thymic atrophy, and immunosuppression
by TCDD and PCBs appear to be associated with
stereospecific binding to the Ah receptor, which is pres-
ent atlowconcentrations inbothlymphoidtissue andlym-
phoid cells (5). This has been supportedingenetic studies
using Ah-responsive and -nonresponsive mouse strains,
including mouse strains congenic at the Ah locus, where
the immunotoxic effects ofTCDD segregate with theAh
genotype. This can be seen in Figure 1, where a dose-
dependent suppression of the antibody response to
trinitrophenylated-lipopolysaccharide antigen occurred
when purified splenic B-cells obtained from Ah-
responsive micewere culturedwithTCDD, butnotwhen
TCDD was cultured with cells from the nonresponsive
strain. In contrast, dexamethasone, another potent im-
munosuppressant that acts via a steroid receptor mech-
anism, did not show these strain differences. In addition
togenetic studies, structure-activity studies showed that
the bindingaffinity ofvarious HAH congeners to the Ah
receptor correlates with their potency to induce im-
munosuppression.
Although immunotoxicity by HAHs is mediated
through binding to the Ah receptor, the mechanisms
responsible for toxicity following interaction of the
receptor-ligand complex with the Ah locus are unknown.
Infact, additional loci maybe involved, as certain tissue-
Table 4. Correlation between host susceptibility and depressed immune function.a
Challenge NK Proliferation Antibody
model cytotoxicity MLR PHA LPS PFC DHR
PYB6 sarcoma 0.45b 0.46* 0.20 0.02 0.22 0.61*
B16F10 melanoma 0.54* 0.02 0.15 0.16 0.15 ND
Listeria 0.01 0.47t 0.37* 0.08 0.01 0.19
Influenza 0.11 0.78* 0.03 0.70* 0.83' ND
Plasmodium 0.24 0.59 0.67 0.64* 0.78t ND
aAbbreviations: MLR, mixed lymphocyte reaction; PHA, phytohemagglutinin; LPS, lipopolysaccharide; PFC; DHR, delayed hypersensitivity re-
sponse; ND, not done.
bCorrelation coefficient as determined by Spearman's Rank Correlation Test (rho values).
* Significant correlation at p < 0.05.
t Significant correlation at p < 0.01.
160CHEMICAL-INDUCED IMMUNOTOXICITY
2500 v
U Ah
(1) * DEX Ah /-
rJ CJDEX Ah -/-
w
2000
1500 1
CL
-J
z
~-500.
0
0 10-10 to-9 g- to-7
CONCENTRATION of TCDD or DEXAMETHASONE (M)
FIGURE 1. Effect of TCDD or dexamethasone (DEX) on TNP-LPS
plaque-forming cells from B-cells obtained from Ah responsive
B6C3F1 and Ah-nonresponsive DBA mice. B-cells were cultured in
the presence ofTCDD or dexamethasone plus TNP-LPS for 4 days
and assayed for plaque forming cells using TNP-coupled SRBCs.
Asterisk (*) denotes significantly different from vehicle response at
p < 0.05. From Luster et al. (24).
specific responses, such as epidermal hyperplasia in hair-
less mice, appear to be regulated by at least two genetic
loci, Ah and hr(23). Immunosuppression by TCDD does
not occur via a cellular depletion mechanism or qualita-
tive and/or quantitative changes in regulatory products,
as has been shown to occurwith corticosteroids (5,18). In
epidermal cell lines, TCDD alters normal patterns of
proliferation and/or differentiation. Likewise, it has been
proposed that TCDD induces similar effects in thymic
epithelial cells and lymphocytes. For example, TCDD
causes terminal differentiation ofthymic epithelial cells
(21) and blocks the terminal differentiation ofmurine B-
lymphocytes into plasma cells (24). Thislatter effect is as-
sociated with qualitative and quantitative changes in
phosphorylated proteins that are related to growth
promoting activity (i.e., tyrosine kinase) (Clark and Lus-
ter, in preparation). Thus, existing data indicate that
TCDD immunotoxicity results from altered patterns of
cell proliferation and differentiation in distinct lymphoid
targets.
Conclusions and Future Direction
The immune system is composed of several cell popu-
lations where maturation ofeach population is subject to
orderly control by endogenous hormones and exogenous
bacterial products. These mediators possess activation,
growth-promotion, and/or differentiation properties, and
are under the influence ofpotent, but not well-understood
regulators. From observations in rodents and limited
studies in humans inadvertently exposed, it is apparent
that a number ofxenobiotics adversely affect the immune
system. This can occur through disruption of cell matu-
ration or regulation, as well as through cytotoxic pro-
cesses. Theseexamples, combinedwith ourcurrectknowl-
edge about the pathogenesis of disease, support the
possibilitythat chemical-induced damage to the immune
systemmaybeassociatedwith awide spectrumofdiverse
pathological conditions, some ofwhich may only become
detectable after alonglatency. Likewise, exposure to im-
munotoxic xenobiotics mightrepresentadditional risksto
individuals with already fragile immune systems (e.g.,
malnutrition, infancy and old age). However, it is impor-
tant that caution be exercised when attempting to ex-
trapolate meaningful conclusions from experimental data
orisolated epidemiological studies to riskassessmentfor
low-level human exposure.
Because ofthe functional heterogeneity ofthe immune
system, efforts to assess chemical-induced immunotoxic-
ity in laboratory animals and humans have historically
beenperformed usingatiered approach withmultiple as-
says. A similar configuration as described here has re-
centlybeen included in EPA's FederalInsecticide, Fungi-
cide and Rodenticide Act regulations for immunotoxicity
testingofbiochemical pesticides. The value ofincorporat-
ingimmunological rodent dataforthetoxicological assess-
ment ofdrugs, chemicals, and biologicals for human risk
assessment hasbeen increasingly accepted. The preced-
ing decade of research has provided a data base of im-
munotoxic and nonimmunotoxic compounds, studies cor-
relatingimmune dysfunction and altered hostresistance,
and abetter standardizedpanel ofmethodsfor detecting
immunomodulatory chemicals. In the near future, re-
search related to methodology is needed to further refine
and validate immune function tests and host resistance
assays, particularly in the rat; develop, refine, andvalidate
better testing methods to evaluate the effects ofchemi-
cal inhalation on lungimmunity; determine the need and
relevance of methods for assessing hematopoietic and
polymorphonuclear leukocyte functions; develop and
evaluate in vitro methodology as screens for detecting
chemical-induced immunotoxicity using rodent and hu-
man immune cells; develop improved methods for evalu-
ating chemical-induced hypersensitivity and autoimmu-
nity; anddevelop atestingbatteryto examine dysfunction
in humans occupationally or environmentally exposed to
chemicals shown to be immunotoxic inlaboratory animals.
In addition to riskassessment, scientists are usingthe
immune system as in vitro model systems for studying
toxic mechanisms at the cellular and molecular levels.
Routine parameters measured intoxicology studies, such
as blood or tissue cellularity, are often considerably less
sensitive indicators of toxicity than immune function
tests. The lymphocyte and macrophage, in particular, pos-
sess a number of characteristics that make them an ap-
propriate model for examining the effects of various
agents on cell maturation andfunction. Amongthese are
their capacity to undergo activation in vitro in response
to antigens or nonspecific stimuli, expression of gene
products that can be used as markers of differentiation,
the identification and availability of specific growth
promotingfactors (e.g., interleukins), and theirpotential
to undergo terminal differentiation resulting in produc-
* TCDD Ah */-
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tion of soluble mediators (e.g., monokines, lymphokines,
orantibody) orprovidingeffectorfunction(e.g., tumortar-
get cell killing).
The authors thank L. Oysterforherhelp in preparingthis manuscript.
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